Careers Media center Contacts

Inspiron withdrawn from circulation

30 May 2019 | News

On 23rd May 2019, Ukraine’s State Inspectorate for Quality Control of Medicines ordered to permanently withdraw from circulation in the country all fenspiride-containing medicinal products and cease production, sale, storage, and use thereof. Arterium Corporation’s Inspiron tablets and syrups have been affected too. The move is inspired by the recommendation of the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) aimed at preventing the realization of risks in cardiovascular patients. Over the past three months, PRAC thoroughly reviewed the lab data provided by Servier, the producer of the original drug having fenspiride as an active pharmaceutical ingredient (API). “Fenspiride molecule has been used in medical practice for over 40 years, and no clinical cases of its side effects with an adverse outcome have been identified thus far. The withdrawal is to prevent the development of possible risks going forward,” Arterium Corporation’s Pharmacovigilance Manager Rimma Battalova commented. “So, there is nothing to worry about for those who used fenspiride-based drugs before – fenspiride molecule is quickly metabolized and does not build up in bodily systems.”

 

Media gallery
PRESS KIT

Here you can find general information about the company intended for journalists and other stakeholders

MEDIA CONTACTS

For all media-related enquiries,
please contact us
e-mail: pr@arterium.ua
mob.: +38050 446 71 20, +38095 278 92 80